Skip to main content

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Eagle Pharmaceuticals, Inc. (EGRX) on Behalf of Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) investors concerning the Company’s possible violations of federal securities laws.

On November 9, 2023, before the market opened, Eagle disclosed that it would not be able to file its quarterly report for the second quarter of 2023 on time because it required additional time to complete its review of potential adjustments relating to the reporting of sales of PEMFEXY. On this news, Eagle’s stock price fell $4.16, or 30.4%, to close at $9.54 per share on November 9, 2023, thereby injuring investors.

After the market closed on November 9, 2023, the Company also disclosed that it was reviewing potential adjustments to reserves for returns and price adjustments of approximately $15.0 million to $20.0 million relating to returns and a price adjustment for PEMFEXY stemming from slower-than-anticipated pull-through from a wholesale customer predominantly due to expiry of inventory. On this news, Eagle’s stock price fell $0.27, or 2.9%, to close at $9.27 per share on November 10, 2023.

Then, on November 29, 2023, Eagle disclosed that Scott Tarriff, the Company’s President and Chief Executive Officer resigned and that the Company’s board of directors accepted the resignation “[a]fter consideration of various alternatives, including termination with or without cause.” On this news, Eagle’s stock price fell $2.55, or 31%, to close at $5.68 per share on November 29, 2023, thereby injuring investors further.

If you purchased Eagle securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to, or visit our website at

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.